Skip to main content

Advertisement

Log in

ASO Visual Abstract: How Often Do Sentinel Lymph Node Biopsy Results Affect Adjuvant Therapy Decisions Among Postmenopausal Women with Early-Stage HR+/HER2 Breast Cancer in the Post-RxPONDER Era?

  • ASO Visual Abstract
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Melissa Pilewskie MD.

Ethics declarations

Disclosure

The preparation of this study was supported in part by NIH/NCi Cancer Center Support Grant No. P30CA008748 to Memorial Sloan Kettering Cancer Center, and this study was presented in poster format at the 23rd Annual Meeting of the American Society of Breast Surgeons, 6–10 April 2022, Las Vegas, NV. Dr. Monica Morrow has received honoraria from Roche and Exact Sciences. All other authors have no relevant conflicts of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pilewskie, M., Sevilimedu, V., Eroglu, I. et al. ASO Visual Abstract: How Often Do Sentinel Lymph Node Biopsy Results Affect Adjuvant Therapy Decisions Among Postmenopausal Women with Early-Stage HR+/HER2 Breast Cancer in the Post-RxPONDER Era?. Ann Surg Oncol 29, 6274–6275 (2022). https://doi.org/10.1245/s10434-022-12246-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-12246-0

Navigation